fasudil has been researched along with Ischemic Attack, Transient in 18 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Since September 1995, the combination of fasudil hydrochloride and ozagrel sodium, an inhibitor of thromboxane A2 synthesis, has been used to treat 60 patients at risk of cerebral vasospasm after aneurysmal subarachnoid hemorrhage." | 7.70 | Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. ( Abe, M; Fukuyama, K; Mineta, T; Nakashima, S; Shimokawa, S; Tabuchi, K, 1998) |
| " Since September 1995, the combination of fasudil hydrochloride and ozagrel sodium, an inhibitor of thromboxane A2 synthesis, has been used to treat 60 patients at risk of cerebral vasospasm after aneurysmal subarachnoid hemorrhage." | 3.70 | Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. ( Abe, M; Fukuyama, K; Mineta, T; Nakashima, S; Shimokawa, S; Tabuchi, K, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 11 (61.11) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, SL | 1 |
| Cipolla, MJ | 1 |
| Yagita, Y | 1 |
| Kitagawa, K | 1 |
| Oyama, N | 1 |
| Yukami, T | 1 |
| Watanabe, A | 1 |
| Sasaki, T | 3 |
| Mochizuki, H | 1 |
| Ohtaki, M | 1 |
| Tranmer, B | 1 |
| Shibuya, M | 13 |
| Suzuki, Y | 13 |
| Hidaka, H | 9 |
| Ichikawa, A | 1 |
| Toshima, Y | 1 |
| Satoh, S | 8 |
| Ikegaki, I | 8 |
| Asano, T | 9 |
| Nakashima, S | 1 |
| Tabuchi, K | 1 |
| Shimokawa, S | 1 |
| Fukuyama, K | 1 |
| Mineta, T | 1 |
| Abe, M | 1 |
| Tachibana, E | 1 |
| Harada, T | 3 |
| Saito, K | 1 |
| Takayasu, M | 4 |
| Yoshida, J | 1 |
| Hitomi, A | 1 |
| Sugita, K | 5 |
| Saito, I | 2 |
| Takakura, K | 2 |
| Nagata, I | 1 |
| Kikuchi, H | 2 |
| Takemae, T | 2 |
| Okamoto, S | 1 |
| Kanamori, M | 1 |
| Okada, T | 1 |
| Kageyama, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Cilostazol-Nimodipine Combined Therapy on Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial[NCT04148105] | Phase 4 | 120 participants (Anticipated) | Interventional | 2019-11-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fasudil and Ischemic Attack, Transient
| Article | Year |
|---|---|
[Signal-transduction therapy].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Calcium | 1996 |
4 trials available for fasudil and Ischemic Attack, Transient
| Article | Year |
|---|---|
[Treatment of cerebral vasospasm by a protein kinase inhibitor AT 877].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Dogs; Double-Blind Method; Humans; Ischemic | 1993 |
Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Aneurysm, Ruptured; Female; Humans; Infu | 1999 |
Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Calcium; Cerebral Infarction; Double-Bli | 1992 |
Dose escalation trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid haemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Blood Pressure; Calcium Channel Blockers | 1990 |
13 other studies available for fasudil and Ischemic Attack, Transient
| Article | Year |
|---|---|
Treatment with low dose fasudil for acute ischemic stroke in chronic hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cerebrovascular Circulation; Chronic Disease | 2017 |
Functional deterioration of endothelial nitric oxide synthase after focal cerebral ischemia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Disease Models, Animal; E | 2013 |
Pretreatment of transient focal cerebral ischemia in rats with the calcium antagonist AT877.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Calcium; Cerebral Arteries; | 1994 |
Thromboxane A2 synthetase inhibitor failed to ameliorate the arterial narrowing during the chronic phase of cerebral vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cerebral Hemorrhage; Dogs; Enzyme Inhibitors | 1997 |
Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Aneurysm, Ruptured; Calcium Channel Bloc | 1998 |
Hemorheological abnormalities in experimental cerebral ischemia and effects of protein kinase inhibitor on blood fluidity.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterial Occlusive Diseases; Blood Viscosity | 2000 |
Possible prophylactic potential of HA1077, a Ca2+ channel antagonist and vasodilator, on chronic cerebral vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Calcium; Cerebrovascular Cir | 1992 |
The effects of HA1077 on the cerebral circulation after subarachnoid haemorrhage in dogs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Flow Velocity; Blood Volume; Brain; Ca | 1991 |
Endothelin: a potential modulator of cerebral vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calcium; Cerebral Arteries; Dogs; Endothelin | 1990 |
Endothelin and the production of cerebral vasospasm in dogs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Blood Pressure; Calcium; Dog | 1989 |
The effects of an intracellular calcium antagonist HA 1077 on delayed cerebral vasospasm in dogs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arteries; Calcium Channel Blockers; Cerebral | 1988 |
Mechanism of action of a novel antivasospasm drug, HA1077.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calcium Channel Blockers; Calcium Chloride; | 1987 |
The effects of HA compound calcium antagonists on delayed cerebral vasospasm in dogs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Calcium Channel Blockers; Ch | 1986 |